Atomoxetine should not be taken within 2 weeks after discontinuing an MAOI or completely avoid taking MAOI. MAO inhibitor (MAOI) should also be taken into account for contraindications. The first one is hypersensitivity but patients known to be hypersensitive to atomoxetine or other constituents of the product should avoid using it. John's Wort.Ī few contraindications should be taken into account for atomoxetine. Carbamazepine and phenobarbital, medicines used to control fits or seizures.Any potassium-depleting diuretics (medicines for eliminating water), e.g.Ergot derivatives used to treat migraine or Parkinson's disease may cause an increase in blood pressure.venlafaxine, imipramine, mirtazapine) should be used with caution when administered with atomoxetine due to possible synergy or synergistic effects on pharmacodynamic effects.īeware of taking reboxetine in combination with: Medicines that affect norepinephrine (e.g.albuterol because it may increase the efficacy of albuterol on the cardiovascular system. ![]() Antihypertensive drugs because it can possibly increase the blood pressure.CYP2D6 inhibitors (e.g., fluoxetine, paroxetine and quinidine) can increase exposure for atomoxetine and it can also increase atomoxetine steady-state plasma concentration.That can increase the plasma concentration of NRIs in the body.īeware of taking atomoxetine in combination with: If people are using sNRI drugs they should not take MAO inhibitors at the same time. What can be considered serious side effects are thoughts of suicide, aggressiveness and hallucinations. Other side effects are urinary retention, constipation, sweating and insomnia. Sexual adverse effects are mostly related to male arousal difficulties and decreased libido in both men and women, but they are significantly less common than with serotonergic drugs. An increase in heart rate and blood pressure have been reported but are usually not clinically important. Selective NRIs are generally well tolerated but the most common side effects reported are headache, dry mouth, abdominal pain, loss of appetite, nausea, vomiting and drowsiness. Īttention deficit hyperactivity disorder (ADHD)Īdverse effects Side effects Reboxetine was first approved for marketing in Europe in 1997, however, in the United States its application for approval was rejected. ![]() Its indication is for acute treatment of depression or major depression disorder. Reboxetine is a selective norepinephrine reuptake inhibitor and acts by binding to the NET and block the reuptake of norepinephrine in the extracellular fluids.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |